The bill directs the NIH Director to create the X‑Labs Initiative, a competitive program that makes long‑term institutional awards to support ‘‘breakthrough biomedical research’’ and related R&D plant. Awards sit in four labeled categories (XL01–XL04) that target basic discovery institutions, resource‑creating centers, intermediary nonprofit funders that regrant to investigators, and planning of new institutions.
The statute changes how NIH can distribute funds: awards can run for up to seven years (with a one‑time renewal for some awards), include large multi‑year funding bands, impose a restriction that many recipients not accept other federal research grants during the award, and allow NIH to use other‑transactions authorities. The program includes reporting, five‑year evaluations, and a public‑transparency requirement for XL03 regranting methods — all designed to test a more institutional, higher‑risk funding model than standard project grants.
At a Glance
What It Does
Establishes the X‑Labs Initiative (statutory Section 404P) to award multi‑year institutional grants in four categories (XL01–XL04), permits awards sized between defined minimums and maximums per fiscal year, and authorizes NIH to use other‑transactions authorities. The Director will run competitive selection, set activity codes, and may terminate awards for noncompliance.
Who It Affects
Nonprofit research organizations, universities, for‑profit entities with nonprofit research subsidiaries, nascent founders planning new nonprofits, and intermediary organizations that regrant funds to research teams. NIH institutes and centers will also be directly affected because they can participate and channel funds under the XL activity code.
Why It Matters
This bill tests an institutional funding model at scale: stable, long‑horizon support for high‑risk, high‑reward science and explicit funding for building R&D plant — a departure from NIH’s investigator‑initiated, project‑based grant culture. It introduces new programmatic flexibility (OT authorities) and formalizes regranting as a tool to reach nontraditional teams.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The X‑Labs Initiative creates a new, statutory vehicle at NIH to make long‑term institutional awards intended to enable scientific programs that conventional, shorter project grants do not support. The program is explicitly designed to (1) stabilize institutions that pursue fundamental discovery, (2) fund the creation of broadly useful scientific resources, (3) provide intermediaries a pool to regrant to risky or unconventional teams, and (4) finance planning to launch new institutions.
Each award is made through a competitive process run by the NIH Director or by NIH institutes and centers in coordination with the Director.
Awards are organized into four categories with distinct expectations. XL01 is for foundational basic science institutions and emphasizes stable funding with minimal reprogramming; XL02 supports resource‑creation projects with clearly defined deliverables; XL03 funds intermediary nonprofit entities that must regrant to U.S.‑based research teams judged unlikely to receive traditional NIH grants and publicly disclose their selection methods; XL04 covers formation and planning of new institutions and is available only as a short, nonrenewable award.
The statute instructs NIH to set an ‘‘XL‑series’’ activity code so institutes can channel funds through the program while preserving program identity.The bill sets concrete size and duration guardrails: XL01–03 awards are constructed in annual amounts between $5 million and $50 million per fiscal year for up to seven consecutive fiscal years, with a possible single renewal of seven more years subject to competitive review, appropriations, and a Director‑set renewal cap to allow turnover. XL04 awards are smaller ($1 million–$5 million per fiscal year) for one to three years and cannot be renewed.
To promote commitment and avoid duplicative federal funding, recipients of XL01–03 awards may not compete for or receive other federal research grants (excluding training grants) during their award period. NIH can terminate and reallocate funds if obligations, deliverables, or eligibility criteria are not met.Administration and oversight combine flexibility with reporting requirements.
The Director may use other‑transactions authorities to implement the program, and any NIH institute may participate within its research focus. The Director must report to key House and Senate committees within one year on program setup and then annually for two years, and perform a program evaluation five years after the first award and every five years thereafter to assess scientific impact, administrative burden, and program effectiveness.
Definitions in the statute cover ‘‘eligible entity,’’ ‘‘focused research organization,’’ ‘‘R&D plant,’’ and other technical terms to guide eligibility and award design.
The Five Things You Need to Know
XL01–XL03 awards must be structured between $5 million and $50 million per fiscal year and may run for 7 consecutive fiscal years; the Director may allow one 7‑year renewal after competitive review and subject to a renewal cap.
An XL04 planning award is capped at $1 million–$5 million per fiscal year, may last 1–3 years, and the statute bars its renewal.
Recipients of XL01, XL02, or XL03 awards cannot compete for or receive other federal research grant funding (training grants excluded) during the award period, effectively forcing a choice between X‑Labs support and conventional NIH grants.
Entities that receive XL03 funding must regrant to U.S.‑based teams deemed unlikely to get traditional NIH grants, use ‘‘innovative methods’’ to select and evaluate those regrants, and publish a public summary of their selection/evaluation method within one year of each regrant.
The Director may employ other‑transactions or similar authorities (permitted under 402(n)(1) or other authorities) to carry out the program, expanding procurement and award flexibility beyond standard NIH grant mechanisms.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishes the X‑Labs Initiative
This subsection creates the statutory program and gives the NIH Director the authority to operate long‑term institutional awards. Practically, it means the initiative is not only a policy memo but a stand‑alone program in the Public Health Service Act, subject to statutory reporting and oversight requirements.
Declares program purposes
The law lists two purposes: catalyzing institutions to conduct breakthrough biomedical research and assisting institutions in acquiring R&D plant. That second purpose explicitly authorizes major facility and equipment investments, signaling that the program can fund capital‑intensive projects that traditional project grants typically do not.
Creates four XL award categories and regrant rules
The statute defines XL01 (basic science institutional support), XL02 (resource creation with defined deliverables), XL03 (intermediaries that regrant), and XL04 (planning new institutions). XL03 has special rules: awardees must regrant to U.S. teams judged unlikely to obtain standard NIH grants, adopt innovative review/evaluation processes, and publish summaries of how they chose and will evaluate regrant recipients — a transparency requirement meant to justify deviating from normal NIH peer review.
Funding bands, durations, and application rules
The bill prescribes funding floors and ceilings and maximum award durations (7 years for XL01–03 with one possible 7‑year renewal; 1–3 years for XL04 with no renewal). Applications go to the Director in forms the Director prescribes. Award sizing is tied to institutional scope, scientific ambition, and programmatic needs, giving NIH discretion to calibrate awards but also creating points of judgment that will shape selection.
Eligibility maintenance and early termination
To remain in good standing, recipients of XL01–03 must not accept other federal research grants during the award period. The Director can suspend or terminate awards for missed deliverables, loss of eligibility, or noncompliance and may revoke remaining funds and reallocate them to new awards, which creates fiscal teeth for enforcement but also administrative work to monitor compliance.
Administration, authority, and reporting
The Director administers the program and may coordinate with NIH institutes and centers, which can participate using the designated XL‑series activity code. The statute expressly permits use of other‑transactions authorities. Reporting includes an initial setup progress report within one year and two more annual reports, plus program evaluations starting five years after the first award and every five years thereafter to judge scientific impact and administrative burden.
Definitions and appropriations
The law defines key terms — eligible entities, focused research organizations, R&D plant, scientific ambition, institutional scope — to constrain eligibility and guide award design. It authorizes ‘‘such sums as may be necessary’’ for FY2026–2031, a permissive authorization that requires annual appropriations to fund the program but does not set a dollar total.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Basic‑science and discovery institutions that need stable, multi‑year revenue streams: XL01 explicitly targets institutions seeking less frequent budget reprogramming and provides long founding‑style support that can protect long‑horizon research from annual grant churn.
- Intermediary nonprofits and focused research organizations that can regrant: XL03 funds enable organizations to seed riskier teams and unconventional projects that traditional NIH peer review typically overlooks, expanding the pipeline of novel ideas.
- Institutions planning new research entities: XL04 provides dedicated planning capital to stand up new labs or centers, lowering the early‑stage cost and risk of founding mission‑driven research organizations.
- NIH institutes and program officers: the XL‑series gives program managers a tool to pursue strategic priorities, incubate novel research ecosystems, and fund R&D plant without shoehorning projects into existing grant mechanisms.
- Regional innovation ecosystems and workforce development: capital support for R&D plant and institution building can create local research infrastructure, jobs, and longer‑term partnerships with universities and industry.
Who Bears the Cost
- NIH and its institutes: administering large, long‑duration institutional awards and regrant portfolios increases program management, monitoring, and evaluation workloads and may require new expertise and processes.
- Current NIH grant applicants and investigator‑led projects: the institutional award model and the prohibition on other federal research grants for recipients could shift pool dynamics and reduce availability of traditional project grants for some applicants.
- Award recipients who accept XL01–03 funds: they must forgo other federal research grants during the award period, a substantial opportunity cost that forces institutions to choose strategic priorities and may concentrate risk.
- Congressional appropriators: the program’s open authorization (‘‘such sums as may be necessary’’) places the cost decision on annual appropriations committees, forcing tradeoffs with other NIH priorities.
- Smaller institutions or nontraditional teams not selected for XL awards: if the program concentrates resources in a few large institutional awards, smaller players may face a tougher funding environment unless regranting under XL03 meaningfully reaches them.
Key Issues
The Core Tension
The central dilemma is whether concentrating large, stable awards in a handful of institutions — with fewer administrative conditions and the option to use flexible contracting authorities — best advances high‑risk, high‑reward science, or whether it undermines the investigator‑driven, competitive grant ecosystem and weakens transparency and oversight by shifting programmatic discretion to NIH leadership.
The bill creates a purposeful tension between flexibility and oversight. By design, long‑horizon institutional awards reduce administrative churn and let institutions plan big, risky science, but they also put large sums under fewer institutional managers.
That concentration can produce efficiency in pursuing ambitious goals but risks entrenching a new set of preferred institutions and reducing the breadth of investigator‑led competition. The statutory ban on other federal research grants for XL01–03 recipients is an especially blunt tool: it creates programmatic clarity and avoids double dipping, but it also forces institutions to forgo traditional funding streams and may deter candidates who rely on a mixed portfolio.
The statute’s authorization to use other‑transactions authorities and its permissive appropriations language accelerate execution and allow nonstandard award terms, but those same features reduce the statutory guardrails that Congress normally uses to control accountability, procurement rules, and auditability. The requirement that XL03 awardees publish their selection/evaluation methods improves transparency, yet the law leaves key evaluative judgments—‘‘scientific ambition,’’ ‘‘programmatic needs,’’ and institutional scope—to the Director’s discretion.
Measuring ‘‘breakthrough’’ outcomes presents a practical problem: breakthrough science can take many years to produce measurable returns, so five‑year evaluations may undercount significant long‑term impact or overemphasize near‑term deliverables.
Operationally, NIH will need new governance: selection panels that can evaluate institutional roadmaps and capital plans; monitoring systems to enforce the ban on parallel federal grants; and metrics that balance risk tolerance with fiduciary oversight. Finally, because the authorization sets no aggregate dollar limit, Congress will effectively decide each year whether to scale the program — the program can remain dormant without appropriations or quickly ramp up if Congress chooses, which makes the program’s future highly dependent on appropriations politics rather than statutory constraints.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.